OTCMKTS:AOBI

American Oriental Bioengineering Competitors

$1.28

0.00 (0.00 %)

(As of 05/7/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.28

▼

$1.28

50-Day Range

$1.20

▼

$3.88

52-Week Range

$0.01

▼

$5.00

Volume1 shs

Average Volume192 shs

Market Capitalization$93,440.00

P/E RatioN/A

Dividend YieldN/A

Beta-14.13

American Oriental Bioengineering (OTCMKTS:AOBI) Vs. STLT, TRPXD, PFSCF, SKVI, EPRSQ, and ROSGQ

Should you be buying AOBI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to American Oriental Bioengineering, including Spotlight Innovation (STLT), Therapix Biosciences (TRPXD), ProMetic Life Sciences (PFSCF), Skinvisible (SKVI), EPIRUS Biopharmaceuticals (EPRSQ), and Rosetta Genomics (ROSGQ).

American Oriental Bioengineering vs. Spotlight Innovation Stock

Spotlight Innovation (OTCMKTS:STLT) and American Oriental Bioengineering (OTCMKTS:AOBI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Earnings and Valuation

This table compares Spotlight Innovation and American Oriental Bioengineering's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spotlight Innovation	N/A	N/A	N/A	N/A	N/A
American Oriental Bioengineering	N/A	N/A	N/A	N/A	N/A

Risk & Volatility

Spotlight Innovation has a beta of -105.24, indicating that its stock price is 10,624% less volatile than the S&P 500. Comparatively, American Oriental Bioengineering has a beta of -14.13, indicating that its stock price is 1,513% less volatile than the S&P 500.

Profitability

This table compares Spotlight Innovation and American Oriental Bioengineering's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spotlight Innovation	N/A	N/A	N/A
American Oriental Bioengineering	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Spotlight Innovation and American Oriental Bioengineering, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spotlight Innovation	0	0	0	0	N/A
American Oriental Bioengineering	0	0	0	0	N/A

Summary

American Oriental Bioengineering beats Spotlight Innovation on 1 of the 1 factors compared between the two stocks.

American Oriental Bioengineering vs. Therapix Biosciences Stock

Therapix Biosciences (OTCMKTS:TRPXD) and American Oriental Bioengineering (OTCMKTS:AOBI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares Therapix Biosciences and American Oriental Bioengineering's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Therapix Biosciences	N/A	N/A	$-4,790,000.00	N/A	N/A
American Oriental Bioengineering	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Therapix Biosciences and American Oriental Bioengineering's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Therapix Biosciences	N/A	N/A	N/A
American Oriental Bioengineering	N/A	N/A	N/A

Insider and Institutional Ownership

14.3% of Therapix Biosciences shares are owned by institutional investors. 30.3% of American Oriental Bioengineering shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Therapix Biosciences and American Oriental Bioengineering, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Therapix Biosciences	0	0	0	0	N/A
American Oriental Bioengineering	0	0	0	0	N/A

American Oriental Bioengineering vs. ProMetic Life Sciences Stock

ProMetic Life Sciences (OTCMKTS:PFSCF) and American Oriental Bioengineering (OTCMKTS:AOBI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Profitability

This table compares ProMetic Life Sciences and American Oriental Bioengineering's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%
American Oriental Bioengineering	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations for ProMetic Life Sciences and American Oriental Bioengineering, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProMetic Life Sciences	0	0	0	0	N/A
American Oriental Bioengineering	0	0	0	0	N/A

Earnings and Valuation

This table compares ProMetic Life Sciences and American Oriental Bioengineering's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMetic Life Sciences	$36.55 million	3.49	$-150,730,000.00	N/A	N/A
American Oriental Bioengineering	N/A	N/A	N/A	N/A	N/A

American Oriental Bioengineering has lower revenue, but higher earnings than ProMetic Life Sciences.

Institutional & Insider Ownership

0.1% of ProMetic Life Sciences shares are held by institutional investors. 30.3% of American Oriental Bioengineering shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

ProMetic Life Sciences has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500. Comparatively, American Oriental Bioengineering has a beta of -14.13, suggesting that its stock price is 1,513% less volatile than the S&P 500.

Summary

American Oriental Bioengineering beats ProMetic Life Sciences on 4 of the 7 factors compared between the two stocks.

American Oriental Bioengineering vs. Skinvisible Stock

Skinvisible (OTCMKTS:SKVI) and American Oriental Bioengineering (OTCMKTS:AOBI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Skinvisible and American Oriental Bioengineering, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skinvisible	0	0	0	0	N/A
American Oriental Bioengineering	0	0	0	0	N/A

Profitability

This table compares Skinvisible and American Oriental Bioengineering's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Skinvisible	-1,027.05%	N/A	-834.18%
American Oriental Bioengineering	N/A	N/A	N/A

Volatility & Risk

Skinvisible has a beta of -0.44, meaning that its share price is 144% less volatile than the S&P 500. Comparatively, American Oriental Bioengineering has a beta of -14.13, meaning that its share price is 1,513% less volatile than the S&P 500.

Valuation & Earnings

This table compares Skinvisible and American Oriental Bioengineering's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skinvisible	$40,000.00	7.38	$-1,700,000.00	N/A	N/A
American Oriental Bioengineering	N/A	N/A	N/A	N/A	N/A

American Oriental Bioengineering has lower revenue, but higher earnings than Skinvisible.

American Oriental Bioengineering vs. EPIRUS Biopharmaceuticals Stock

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) and American Oriental Bioengineering (OTCMKTS:AOBI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Risk and Volatility

EPIRUS Biopharmaceuticals has a beta of 6.03, suggesting that its share price is 503% more volatile than the S&P 500. Comparatively, American Oriental Bioengineering has a beta of -14.13, suggesting that its share price is 1,513% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for EPIRUS Biopharmaceuticals and American Oriental Bioengineering, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EPIRUS Biopharmaceuticals	0	0	0	0	N/A
American Oriental Bioengineering	0	0	0	0	N/A

Profitability

This table compares EPIRUS Biopharmaceuticals and American Oriental Bioengineering's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EPIRUS Biopharmaceuticals	N/A	N/A	N/A
American Oriental Bioengineering	N/A	N/A	N/A

Earnings and Valuation

This table compares EPIRUS Biopharmaceuticals and American Oriental Bioengineering's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EPIRUS Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
American Oriental Bioengineering	N/A	N/A	N/A	N/A	N/A

Summary

EPIRUS Biopharmaceuticals beats American Oriental Bioengineering on 1 of the 1 factors compared between the two stocks.

American Oriental Bioengineering vs. Rosetta Genomics Stock

American Oriental Bioengineering (OTCMKTS:AOBI) and Rosetta Genomics (OTCMKTS:ROSGQ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Earnings and Valuation

This table compares American Oriental Bioengineering and Rosetta Genomics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
American Oriental Bioengineering	N/A	N/A	N/A	N/A	N/A
Rosetta Genomics	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares American Oriental Bioengineering and Rosetta Genomics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
American Oriental Bioengineering	N/A	N/A	N/A
Rosetta Genomics	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for American Oriental Bioengineering and Rosetta Genomics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
American Oriental Bioengineering	0	0	0	0	N/A
Rosetta Genomics	0	0	0	0	N/A

Risk and Volatility

American Oriental Bioengineering has a beta of -14.13, indicating that its stock price is 1,513% less volatile than the S&P 500. Comparatively, Rosetta Genomics has a beta of 6.39, indicating that its stock price is 539% more volatile than the S&P 500.

Summary

Rosetta Genomics beats American Oriental Bioengineering on 1 of the 1 factors compared between the two stocks.